Biotechnology News and Research

RSS

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

LinkMed reports increased sales revenues for 2009 fourth quarter

“Operating income in 2009 was SEK 18.7 million despite non-recurring costs of SEK 3.9 million in the second half of the year related to the transition to an in-house sales organi-zation in the transplantation sector".

23 Feb 2010

Enzymerx completes enrollment for clinical trial of pegsitacase

EnzymeRx, LLC, a clinical-stage biotechnology company, announced completion of the enrollment of its first clinical trial of pegsitacase (formerly called Uricase-PEG 20), and the recent launch of a second clinical study. Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

22 Feb 2010

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

OrbiMed, a leading investment management firm focused on the healthcare sector, is pleased to announce the launch of its next venture capital fund, Caduceus Private Investments IV, LP, with $550 million in limited partner commitments. Approximately 80% of the new fund’s capital is from returning investors, and the fund’s partners include some of the largest pension plans, endowments, foundations, and sovereign funds globally.

22 Feb 2010

WuXi PharmaTech's Suzhou non-clinical safety testing facility receives AAALAC accreditation

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its Suzhou non-clinical safety testing facility received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). As a result of an extensive on-site evaluation, AAALAC determined that WuXi PharmaTech's facility meets the highest standards of animal care and research practices.

22 Feb 2010

Life Technologies completes and settles previously announced Senior Notes offering

Life Technologies Corporation today announced it has completed and settled the previously announced offering of $250 million aggregate principal amount of 3.375% Senior Notes due 2013 at an issue price of 99.953 percent; $500 million aggregate principal amount of 4.400% Senior Notes due 2015 at an issue price of 99.668 percent; and $750 million aggregate principal amount of 6.000% Senior Notes due 2020 at an issue price of 99.796 percent. The notes will pay interest on a semi-annual basis.

20 Feb 2010

El Tejano Magazine article: Medical innovation and research help many Americans live longer, healthier

An article that recently appeared in El Tejano Magazine highlighted the fact that many Americans are living longer, healthier and more productive lives because of medical innovation and research.

20 Feb 2010

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia™ (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.

20 Feb 2010

BioFlorida launches The BioFlorida Institute to create programs to improve science education

BioFlorida, the statewide trade association founded in 1997 to advance Florida’s bioscience industry, has approved a plan to launch The BioFlorida Institute, a not-for-profit foundation focused on education, professional development and industry resources. The Institute, working in partnership with BioFlorida, will create programs to improve science education and support bioscience entrepreneurs and scientists throughout the state.

19 Feb 2010

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Novavax, Inc. today presented to the world's leading pandemic influenza vaccine experts a summary of the recent preliminary safety and immunogenicity data from its Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study in Mexico.

19 Feb 2010

United Therapeutics announces withdrawal of Tyvaso European MAA for treatment of PAH

United Therapeutics Corporation announced today that it has withdrawn its Marketing Authorization Application (MAA) for Tyvaso (treprostinil sodium) 0.6 mg/ml nebuliser solution for the treatment of pulmonary arterial hypertension (PAH) in the European Union.

19 Feb 2010

PharmaTelevision launches major new services to meet growing demands of pharmaceutical industry

PharmaTelevision Ltd announced today the launch of major new services to meet the growing demand for the production and dissemination of rich media content in the pharmaceutical and biotechnology sector. The company, a subsidiary of PharmaVentures, already provides the only online television channel dedicated to the bio-pharma industry, offering daily television news, analysis and feature interviews.

19 Feb 2010

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

PsychoGenics Inc. today announced the establishment of an exclusive alliance with Dr. Jan Kehr, an internationally recognized expert in experimental neuropharmacology, to provide specialized microdialysis services to complement PsychoGenics’ in vivo testing capabilities.

19 Feb 2010

Researchers use Life Technologies’ next-generation sequencing instruments for cancer research

Life Technologies Corporation today announced the publication of two key scientific papers that highlight the utility of next-generation sequencing instruments in better understanding disease and the genetic differences that cause diversity within and between human populations. The Applied Biosystems SOLiD™ System was used in both of these research studies.

19 Feb 2010

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious human diseases such as HIV and cardiovascular diseases, announced results from its prophylactic HIV vaccine (VRX1023) study in Rhesus Macaque monkeys during a presentation today at the 2010 Annual Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, CA.

19 Feb 2010

Pharmaceutical and biotechnology companies working on nearly 200 new medicines to treat diabetes

A Stratton Spotlight article recently highlighted a Centers for Disease Control and Prevention (CDC) survey that showed a dramatic rise in the number of diabetes cases during the last 10 years and noted that pharmaceutical research and biotechnology companies are working on nearly 200 new medicines to treat this debilitating disease.

19 Feb 2010

RainDance Technologies enters into strategic agreement with Applied Biosystems

RainDance Technologies, Inc., a leading provider of innovative microdroplet-based solutions for human health and disease research, and Applied Biosystems, part of Life Technologies Corporation, announced today they have entered into a strategic agreement to co-market the first solution that combines microdroplet PCR-based sequence enrichment with next-generation sequencing.

19 Feb 2010

FDA approves Rituxan-FC combination therapy for CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).

18 Feb 2010

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus), today announced that it presented the results of a preclinical study on a prototype HIV/AIDS vaccine at the Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

18 Feb 2010

Rituxan, intended for patients with CLL receives FDA approval

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.

18 Feb 2010

Biotechnology News and Research

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

LinkMed reports increased sales revenues for 2009 fourth quarter

Enzymerx completes enrollment for clinical trial of pegsitacase

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

WuXi PharmaTech's Suzhou non-clinical safety testing facility receives AAALAC accreditation

Life Technologies completes and settles previously announced Senior Notes offering

El Tejano Magazine article: Medical innovation and research help many Americans live longer, healthier

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

BioFlorida launches The BioFlorida Institute to create programs to improve science education

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

United Therapeutics announces withdrawal of Tyvaso European MAA for treatment of PAH

PharmaTelevision launches major new services to meet growing demands of pharmaceutical industry

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

Researchers use Life Technologies’ next-generation sequencing instruments for cancer research

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

Pharmaceutical and biotechnology companies working on nearly 200 new medicines to treat diabetes

RainDance Technologies enters into strategic agreement with Applied Biosystems

FDA approves Rituxan-FC combination therapy for CLL

GeoVax Labs presents results of preclinical study on prototype HIV/AIDS vaccine at CROI

Rituxan, intended for patients with CLL receives FDA approval

Biotechnology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News